SRPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SRPT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading below key moving averages, momentum is weak, and both proprietary signals show no buy setup today. Given the bearish technical trend, mixed-to-negative Wall Street tone, and hedge fund selling, the better call is to avoid buying now and wait for a clearer turnaround.
Current pre-market price is 17.28, slightly below the pivot at 17.661. MACD histogram is negative at -0.188 and still contracting, RSI_6 is 43.511, which is neutral but weak, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Support sits at 16.516 and 15.809, while resistance is 18.806 and 19.514. Overall, the trend remains bearish and the stock is not showing a strong reversal signal.
Recent analyst updates include several price target raises, notably Wedbush to $35, Morgan Stanley to $25, Oppenheimer to $37, Mizuho to $31, and RBC/Evercore around $19, reflecting ongoing optimism that some pipeline assets may create longer-term value. March data on SRP-1001 and SRP-1003 was described as promising by multiple firms, and the planned sNDA submission for Amondys/Vyondys was viewed positively.
No news was reported in the past week, so there is no fresh event-driven catalyst. The most recent outlook remains mixed, with Evercore lowering its target to $19 and H.C. Wainwright reiterating Sell with a $5 target, highlighting concerns around Elevidys and weak downside risk/reward. Hedge funds are selling aggressively, while insiders are neutral. The stock trend model also points to weakness over the next day, week, and month.
No reliable latest-quarter financial snapshot was available, so quarterly revenue and earnings growth cannot be assessed here. The missing financial data limits confirmation of whether recent business performance is improving or deteriorating, which adds uncertainty for a long-term beginner investor.
Analyst sentiment is mixed but tilted cautiously positive on target prices and cautious on ratings. Recent target changes have been split between raises and trims, with several firms maintaining Outperform/Equal Weight, while others keep Sell ratings. Wall Street appears divided: bulls focus on pipeline optionality and clinical progress, while bears emphasize execution risk, Elevidys concerns, and limited near-term upside. Overall, the pros and cons view is mixed, but the bearish calls and weak technicals outweigh the bullish targets today.
